Cardiac microinjury measured by troponin t predicts collagen metabolism in adults aged ≫65 years with heart failure

Circulation: Heart Failure

Volumn 5, Issue 4, 2012, Pages 406-413

  Kop, Willem J ^a   Gottdiener, John S ^a   DeFilippi, Christopher R ^a   Barasch, Eddy ^c   Seliger, Stephen L ^a   Jenny, Nancy S ^d   Christenson, Robert H ^b  

^a TILBURG UNIVERSITY   (Netherlands)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c STONY BROOK UNIVERSITY   (United States)

^d UNIVERSITY OF VERMONT   (United States)

Author keywords

Collagen metabolism; Fibrosis; Heart failure; Myocardial microinjury; Risk factors; Troponin T

Indexed keywords

AMINOTERMINAL PROPEPTIDE OF PROCOLLAGEN III; BIOLOGICAL MARKER; CARBOXYTERMINAL PROPEPTIDE OF PROCOLLAGEN TYPE 1; CARBOXYTERMINAL TELOPEPTIDE OF TYPE I COLLAGEN; COLLAGEN; PROCOLLAGEN; TROPONIN T; UNCLASSIFIED DRUG;

AGED; ARTICLE; CARDIOVASCULAR RISK; CARDITIS; COLLAGEN METABOLISM; DEMOGRAPHY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HEART FAILURE; HEART MUSCLE INJURY; HUMAN; MAJOR CLINICAL STUDY; MALE; MYOCARDIAL MICROINJURY; PRIORITY JOURNAL; SENSITIVITY ANALYSIS;

AGE FACTORS; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; COLLAGEN; COLLAGEN TYPE I; FEMALE; FIBROSIS; HEART FAILURE; HUMANS; LINEAR MODELS; LONGITUDINAL STUDIES; MALE; MULTIVARIATE ANALYSIS; MYOCARDIUM; PEPTIDE FRAGMENTS; PEPTIDES; PREDICTIVE VALUE OF TESTS; PROCOLLAGEN; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TROPONIN T; UP-REGULATION;

EID: 84864592311     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.111.965327     Document Type: Article

References (41)

1. Gonzalez A, Lopez B, Ravassa S, Beaumont J, Arias T, Hermida N, Zudaire A, Diez J. Biochemical markers of myocardial remodelling in hypertensive heart disease. Cardiovasc Res. 2009;81:509-518.
2. Weber KT. From inflammation to fibrosis: a stiff stretch of highway. Hypertension. 2004;43:716-719.
3. de Souza RR. Aging of myocardial collagen. Biogerontology. 2002;3:325-335.
4. Lombardi R, Betocchi S, Losi MA, Tocchetti CG, Aversa M, Miranda M, D'Alessandro G, Cacace A, Ciampi Q, Chiariello M. Myocardial collagen turnover in hypertrophic cardiomyopathy. Circulation. 2003;108: 1455-1460.
5. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation. 1991;83:1849-1865.
6. Thygesen K, Alpert JS, White HD, Jaffe AS, Apple FS, Galvani M, Katus HA, Newby LK, Ravkilde J, Chaitman B, Clemmensen PM, Dellborg M, Hod H, Porela P, Underwood R, Bax JJ, Beller GA, Bonow R, Van der Wall EE, Bassand JP, Wijns W, Ferguson TB, Steg PG, Uretsky BF, Williams DO, Armstrong PW, Antman EM, Fox KA, Hamm CW, Ohman EM, Simoons ML, Poole-Wilson PA, Gurfinkel EP, Lopez-Sendon JL, Pais P, Mendis S, Zhu JR, Wallentin LC, Fernandez-Aviles F, Fox KM, Parkhomenko AN, Priori SG, Tendera M, Voipio-Pulkki LM, Vahanian A, Camm AJ, De CR, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Morais J, Brener S, Harrington R, Morrow D, Lim M, Martinez-Rios MA, Steinhubl S, Levine GN, Gibler WB, Goff D, Tubaro M, Dudek D, Al-Attar N. Universal definition of myocardial infarction. Circulation. 2007;116:2634-2653.
7. Giannitsis E, Kurz K, Hallermayer K, Jarausch J, Jaffe AS, Katus HA. Analytical validation of a high-sensitivity cardiac troponin T assay. Clin Chem. 2010;56:254-261.
8. deFilippi CR, De Lemos JA, Christenson RH, Gottdiener JS, Kop WJ, Zhan M, Seliger SL. Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults. JAMA. 2010;304:2494-2502.
9. Laviades C, Varo N, Fernandez J, Mayor G, Gil MJ, Monreal I, Diez J. Abnormalities of the extracellular degradation of collagen type I in essential hypertension. Circulation. 1998;98:535-540.
10. Cicoira M, Rossi A, Bonapace S, Zanolla L, Golia G, Franceschini L, Caruso B, Marino PN, Zardini P. Independent and additional prognostic value of aminoterminal propeptide of type III procollagen circulating levels in patients with chronic heart failure. J Card Fail. 2004;10: 403-411.
11. Izawa H, Murohara T, Nagata K, Isobe S, Asano H, Amano T, Ichihara S, Kato T, Ohshima S, Murase Y, Iino S, Obata K, Noda A, Okumura K, Yokota M. Mineralocorticoid receptor antagonism ameliorates left ventricular diastolic dysfunction and myocardial fibrosis in mildly symptomatic patients with idiopathic dilated cardiomyopathy: a pilot study. Circulation. 2005;112:2940-2945.
12. Schwartzkopff B, Fassbach M, Pelzer B, Brehm M, Strauer BE. Elevated serum markers of collagen degradation in patients with mild to moderate dilated cardiomyopathy. Eur J Heart Fail. 2002;4:439-434.
13. Weber KT. Monitoring tissue repair and fibrosis from a distance. Circulation. 1997;96:2488-2492.
14. Cuspidi C, Ciulla M, Zanchetti A. Hypertensive myocardial fibrosis. Nephrol Dial Transplant. 2006;21:20-23.
15. Klappacher G, Franzen P, Haab D, Mehrabi M, Binder M, Plesch K, Pacher R, Grimm M, Pribill I, Eichler HG, Glochar HD. Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosis. Am J Cardiol. 1995;75:913-918.
16. Lopez B, Gonzalez A, Diez J. Circulating biomarkers of collagen metabolism in cardiac diseases. Circulation. 2010;121:1645-1654.
17. Diez J, Laviades C, Mayor G, Gil MJ, Monreal I. Increased serum concentrations of procollagen peptides in essential hypertension. Relation to cardiac alterations. Circulation. 1995;91:1450-1456.
18. Fried LP, Borhani NO, Enright P, Furberg CD, Gardin JM, Kronmal RA, Kuller LH, Manolio TA, Mittelmark MB, Newman A, O'Leary DH, Psaty B, Rautaharju P, Tracy R. The Cardiovascular Health Study: design and rationale. Ann Epidemiol. 1991;1:263-276.
19. Barasch E, Gottdiener JS, Aurigemma G, Kitzman DW, Han J, Kop WJ, Tracy RP. Association between elevated fibrosis markers and heart failure in the elderly: the Cardiovascular Health Study. Circ Heart Fail. 2009;2:303-310.
20. Kop WJ, Kuhl EA, Barasch E, Jenny NS, Gottlieb SS, Gottdiener JS. Association between depressive symptoms and fibrosis markers: the Cardiovascular Health Study. Brain Behav Immun. 2010;24:229-235.
21. Lewis MR, Callas PW, Jenny NS, Tracy RP. Longitudinal stability of coagulation, fibrinolysis, and inflammation factors in stored plasma samples. Thromb Haemost. 2001;86:1495-1500.
22. Agarwal SK, Avery CL, Ballantyne CM, Catellier D, Nambi V, Saunders J, Sharrett AR, Coresh J, Heiss G, Hoogeveen RC. Sources of variability in measurements of cardiac troponin T in a community-based sample: the atherosclerosis Risk In Communities study. Clin Chem. 2011;57: 891-897.
23. Gottdiener JS, Arnold AM, Aurigemma GP, Polak JF, Tracy RP, Kitzman DW, Gardin JM, Rutledge JE, Boineau RC. Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study. J Am Coll Cardiol. 2000;35:1628-1637.
24. Bovill EG, Bild DE, Heiss G, Kuller LH, Lee MH, Rock R, Wahl PW. White blood cell counts in persons aged 65 years or more from the cardiovascular health study. Correlations with baseline clinical and demographic characteristics. Am J Epidemiol. 1996;143:1107-1115.
25. Cushman M, Cornell ES, Howard PR, Bovill EG, Tracy RP. Laboratory methods and quality assurance in the Cardiovascular Health Study. Clin Chem. 1995;41:264-270.
26. Risteli J, Niemi S, Trivedi P, Maentausta O, Mowat AP, Risteli L. Rapid equilibrium radioimmunoassay for the amino-terminal propeptide of human type III procollagen. Clin Chem. 1988;34:715-718.
27. Macy EM, Hayes TE, Tracy RP. Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. Clin Chem. 1997;43:52-58.
28. deFilippi CR, Christenson RH, Gottdiener JS, Kop WJ, Seliger SL. Dynamic cardiovascular risk assessment in elderly people. The role of repeated N-terminal pro-B-type natriuretic peptide testing. J Am Coll Cardiol. 2010;55:441-450.
29. Pencina MJ, D'Agostino RB Sr, Larson MG, Massaro JM, Vasan RS. Predicting the 30-year risk of cardiovascular disease: the Framingham Heart Study. Circulation. 2009;119:3078-3084.
30. Wu AH, Lu QA, Todd J, Moecks J, Wians F. Short- and long-term biological variation in cardiac troponin I measured with a high-sensitivity assay: implications for clinical practice. Clin Chem. 2009;55:52-58.
31. Kwon DH, Halley CM, Carrigan TP, Zysek V, Popovic ZB, Setser R, Schoenhagen P, Starling RC, Flamm SD, Desai MY. Extent of left ventricular scar predicts outcomes in ischemic cardiomyopathy patients with significantly reduced systolic function: a delayed hyperenhancement cardiac magnetic resonance study. J Am Coll Cardiol Cardiovasc Imaging. 2009;2:34-44.
32. Cho JR, Park S, Choi BW, Kang SM, Ha JW, Chung N, Choe KO, Cho SY, Rim SJ. Delayed enhancement magnetic resonance imaging is a significant prognostic factor in patients with non-ischemic cardiomyopathy. Circ J. 2010;74:476-483.
33. Querejeta R, Lopez B, Gonzalez A, Sanchez E, Larman M, Martinez Ubago JL, Diez J. Increased collagen type I synthesis in patients with heart failure of hypertensive origin: relation to myocardial fibrosis. Circulation. 2004;110:1263-1268.
34. Martos R, Baugh J, Ledwidge M, O'Loughlin C, Murphy NF, Conlon C, Patle A, Donnelly SC, McDonald K. Diagnosis of heart failure with preserved ejection fraction: improved accuracy with the use of markers of collagen turnover. Eur J Heart Fail. 2009;11:191-197.
35. Malizia G, Giannuoli G, Caltagirone M, Pisa R, Pagliaro L. Procollagen type I production by hepatocytes: a marker of progressive liver disease? Lancet. 1987;2:1055-1057.
36. Garnero P, Vergnaud P, Hoyle N. Evaluation of a fully automated serum assay for total N-terminal propeptide of type I collagen in postmenopausal osteoporosis. Clin Chem. 2008;54:188-196.
37. Kania G, Blyszczuk P, Eriksson U. Mechanisms of cardiac fibrosis in inflammatory heart disease. Trends Cardiovasc Med. 2009;19:247-252.
38. Wang W, Schulze CJ, Suarez-Pinzon WL, Dyck JR, Sawicki G, Schulz R. Intracellular action of matrix metalloproteinase-2 accounts for acute myocardial ischemia and reperfusion injury. Circulation. 2002;106: 1543-1549.
39. Zannad F, Alla F, Dousset B, Perez A, Pitt B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the Randomized Aldactone Evaluation Study (RALES). RALES Investigators. Circulation. 2000;102:2700-2706.
40. Iraqi W, Rossignol P, Angioi M, Fay R, Nuee J, Ketelslegers JM, Vincent J, Pitt B, Zannad F. Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study. Circulation. 2009;119:2471-2479.
41. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11-21.